The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is a progressive, neurodegenerative disease that affects memory, thinking, and behavior and places a substantial economic burden on caregivers and healthcare systems. This early-phase study aimed to model lecanemab, a humanized monoclonal antibody targeting amyloid protofibrils, for patients with early AD, and estimate the potential value-based price (VBP) of lecanemab + standard of care (SoC) compared to SoC alone given an expected product profile of lecanemab informed by data from a phase II trial from payer and societal perspectives using a broad range of willingness-to-pay (WTP) thresholds in the USA.

Methods

A disease simulation model was used to capture how key AD pathology components relate to the clinical and economic presentatio

SUBMITTER: Tahami Monfared AA 

PROVIDER: S-EPMC9338185 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature